Health & Fitness
Health and Fitness
Health and Fitness
Thu, February 24, 2011Wed, February 23, 2011Tue, February 22, 2011Mon, February 21, 2011Sun, February 20, 2011Fri, February 18, 2011Thu, February 17, 2011Wed, February 16, 2011Tue, February 15, 2011Mon, February 14, 2011Fri, February 11, 2011Thu, February 10, 2011Wed, February 9, 2011Tue, February 8, 2011Biomoda Receives Notice of Allowance on Patent Application for Method of Analyzing Cancer Cells
Published in Health and Fitness on Wednesday, February 16th 2011 at 5:06 GMT by Market Wire
ALBUQUERQUE, N.M.--([ BUSINESS WIRE ])--Cancer diagnostics company Biomoda, Inc. (OTCBB: BMOD) ([ www.biomoda.com ]) received Notice of Allowance for a U.S. Patent application on a quantitative method for scoring cells labeled with the [ CyPath® ] assay to determine whether cells are dysplastic or carcinomic by measuring the photon emission rate.
"Lab technicians anywhere in the world will have a measurable, quantitative system to accurately and inexpensively read body fluid and tissue samples for cancer cells."
aThis invention is an important weapon in our arsenal of cancer diagnostic tools because it provides the objective methodology for reading samples labeled with the CyPath® reagent,a said Biomoda President John Cousins. aLab technicians anywhere in the world will have a measurable, quantitative system to accurately and inexpensively read body fluid and tissue samples for cancer cells.a
Biomodaa™s CyPath® reagent for the early detection of cancers is based on meso-tetra (4 carboxyphenyl) porphine or TCPP, a porphyrin compound that binds to cancer cells and fluoresces under specific frequencies of light. The allowed claims protect a system for verifying the spectral signature of TCPP optically and measuring the photon emission rate of TCPP-stained cancerous and precancerous cells.
The new invention titled aMethod for Detecting and Prognosing Pre-Cancerous Cells Using 5, 10, 15, 20-Tetrakis (Carboxyphenyl) Porphine,a will be Biomodaa™s fourth U.S. patent. Biomoda also has patents issued in Japan, Mexico, and Australia and patents pending in Europe and Canada.
About Biomoda
Biomoda ([ www.biomoda.com ]) is focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer. In addition to its first product for lung cancer, diagnostic assays for cervical, breast, colorectal, bladder, and oral cancers are targeted for development.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on estimates, projections, beliefs and assumptions of Biomoda management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results. Actual results could differ materially from those projected in forward-looking statements due to a variety of factors, which are described from time to time in the Companya™s filings with the Securities and Exchange Commission, including those under the heading "Risk Factors" in the Company's Annual Report on Form 10-K filed with the SEC on March 30, 2010. Forward-looking statements are made as of the date of this press release and are subject to change without notice.
